Radioiodine remnant ablation in low-risk differentiated thyroid cancer patients who had R0 dissection is an over treatment

نویسندگان

  • Chandrasekhar Bal
  • Sanjana Ballal
  • Ramya Soundararajan
  • Saurav Chopra
  • Aayushi Garg
چکیده

OBJECTIVE Evaluate the success rate of first high dose 100 mCi (3.7 GBq) radioiodine remnant ablation (RRA) in low-risk differentiated thyroid cancer (DTC) patients after surgery and determine factors influencing the success. MATERIAL AND METHOD Between 1994 and 2011, a retrospective analysis was performed of 166 low-risk DTC patients after surgery (age range 18-76 years, mean age 38 years, 147 women and 19 men) with primary tumor > 1 cm of diameter stage 52 pT1pN0, 85 pT2pN0, 12 pT3pN0, and 17 pTxN0 underwent high dose 100 mCi (3.7 GBq) RRA. Successful RRA was defined as visually undetectable thyroid bed activity or elsewhere on the first follow-up whole body scan (WBS) six to 12 months after RRA and the stimulated thyroglobulin (st-Tg) levels < 2 ng/mL at the same time of follow-up WBS and without interfering thyroglobulin antibodies (TgAb). Additional 1-131 treatment was individualized depending on clinical characteristics with 100 to 150 mCi (3.7-5.5 GBq) 1-131 six to 12 months intervals to achieve no thyroid bed uptake. RESULTS Successful RRA was achieved in 122 of the 166 patients (73.5%). Failure by both criteria was seen in nine patients (5.4%). Of the 44 patients with ablation failure, additional I-131 treatment was individualized in 26 patients (59.1%). St-Tg levels at time of ablation and tumor size had significance influences on the success of RRA. The st-Tg levels at time of ablation were 7.5 +/- 11.5 ng/mL (0.1-80.3) in the ablation success group as compared with the ablation failure group of 24.1 +/- 24.9 ng/mL (1.3-97), p-value < 0.001. Patients with ablation failure group had statistical significance of average tumor size greater than patients with ablation success group (3.2 +/- 1.1 and 2.7 +/- 1.1 cm), p-value = 0.012. CONCLUSION The efficacy of first high dose RRA in low-risk DTC after surgery shows comparable rates with those reported in the literature. The two factors influencing ablation success are st-Tg levels at time of ablation and tumor size.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

How to manage patients with undetectable thyroglobulin but thyroid residue after radioiodine ablative therapy in differentiated thyroid carcinoma, retreatment or observation?

Introduction:Differentiated thyroid carcinoma (DTC) follow-up after thyroidectomy and radioiodine-ablation is performed mainly by thyroglobulin (Tg), diagnostic iodine-131 whole body scan (DxWBS) and sonography. Some patients with undetectable Tg have thyroid-bed uptake after ablation in whom decision making regarding the need for retreatment is still controversial. Me...

متن کامل

Thyroid hormone replacement one day before 131I therapy in patients with well-differentiated thyroid cancer

Objective: The current study aimed to determine the efficacy of radioiodine-131 (131I) ablation therapy with thyroid hormone replacement one day before 131I administration in patients with well-differentiated thyroid cancer (DTC). Methods: This retrospective study included 29 patients who underwent 131I therapies twice for DTC during 6-12 months.  Since all the patients obviously had residual l...

متن کامل

Recombinant human thyroid-stimulating hormone in radioiodine thyroid remnant ablation.

BACKGROUND To prevent the unwarranted effects of post-thyroidectomy hypothyroidism prior to radiodine (RAI) ablation, patients with well-differentiated thyroid cancer can currently undergo this treatment while in a euthyroid state. This is achieved with the use of recombinant human thyroid-stimulating hormone (rhTSH) injections prior to the ablation. OBJECTIVES To demonstrate the efficacy of ...

متن کامل

Low versus high radioiodine activity for ablation of the thyroid remnant after thyroidectomy in Han Chinese with low-risk differentiated thyroid cancer

AIM The aim of this study was to compare the efficacy and adverse effects of radioiodine (131I) therapy between two groups of patients with low-risk differentiated thyroid cancer (DTC) who received 30 mCi or 100 mCi radioiodine for ablation of the thyroid remnant after total thyroidectomy. METHODS The study cohort was 173 patients, 85 of whom were given 30 mCi of radioiodine and the others we...

متن کامل

Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer

Various studies have demonstrated the safety and efficacy of recombinant human thyroid-stimulating hormone (rhTSH) for radioiodine remnant ablation. On this basis, rhTSH was approved in Europe for the radioiodine ablation of low-risk differentiated thyroid cancer (DTC) during thyroid hormone therapy with L-thyroxine (L-T4). Moreover, in December 2007, the US Federal Drug Administration approved...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 4  شماره 

صفحات  -

تاریخ انتشار 2013